PTHS logo

PTHS Pelthos Therapeutics Inc.

New York Stock Exchange Arca · Biotechnology · Healthcare

$6.38
-0.61 (-8.73%)

Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exc…

Market Cap: $25.08Mpelthos.com

Price

No data yet.

Social Signal Score

39
5d
—
30d
35
2 mentions
—
60d
42
3 mentions
—
90d
42
3 mentions
—
news: 3

Analyst Ratings

4 analysts
Buyconsensus
Strong Buy 0Buy 4Hold 0Sell 0Strong Sell 0
Avg price target$38.75+507.4%
Low $21Median $35High $64
Current Consensus

Revenue

$15.39M
$0.00$5.20M$10.40M$15.60M
Dec 2023Sep 2026

Analyst Estimates

FY2025
$-15.98
$-20.33–$-10.16
5 analysts
FY2026
$-15.64
$-19.48–$-13.70
4 analysts
FY2027
$-4.91
$-11.69–$-1.09
3 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Scott Plesha
Sector
Healthcare
Industry
Biotechnology
Employees
92
Beta
3.11
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
-2.06
pelthos.com